Study guide

14.2 Obesity, Weight Management & Healthy Lifestyle Counseling

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

14.2 Obesity, Weight Management & Healthy Lifestyle Counseling

Key Takeaways Explain This Topic AI

Obesity is a BMI of 30 or higher (27.5 or higher in Asian adults), and a waist circumference over 35 inches signals central adiposity in women.

The USPSTF recommends offering or referring adults with a BMI of 30 or higher to intensive, multicomponent behavioral interventions (grade B).

Adults need 150–300 minutes of moderate (or 75–150 minutes of vigorous) aerobic activity weekly plus muscle strengthening on at least 2 days (Physical Activity Guidelines, 2nd edition).

Anti-obesity medications are contraindicated in pregnancy; semaglutide is stopped at least 2 months before conception, and phentermine-topiramate requires a REMS because topiramate causes oral clefts.

Tirzepatide can reduce oral contraceptive absorption, so patients should switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase.

Last updated: October 2026

Assessment

  • Category BMI (kg/m²) Asian-Ancestry Cutoffs
  • Overweight 25.0–29.9 23.0–27.4
  • Obesity class I 30.0–34.9 27.5 or higher
  • Obesity class II 35.0–39.9
  • Obesity class III 40 or higher

BMI misclassifies some patients, so add waist circumference (over 35 inches / 88 cm in women) and assess weight-related conditions: type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, metabolic dysfunction–associated steatotic liver disease (MASLD), PCOS, infertility, osteoarthritis, GERD, urinary incontinence, depression, and several cancers (endometrial, postmenopausal breast, colorectal).

Review weight-promoting drugs: antipsychotics, mirtazapine, some SSRIs (paroxetine), insulin and sulfonylureas, glucocorticoids, gabapentinoids, and DMPA (which can add weight in some users). Screen for binge-eating disorder before prescribing; lisdexamfetamine is approved for binge-eating disorder.

Use person-first, nonstigmatizing language ("a patient with obesity"), and ask permission before discussing weight.

Behavioral Counseling

USPSTF (grade B): Offer or refer adults with a BMI of 30 or higher to intensive, multicomponent behavioral interventions (typically 12 or more sessions in the first year) combining diet, physical activity, self-monitoring, and goal setting. A 5%–10% weight loss improves blood pressure, glucose, lipids, and ovulation in PCOS.

The USPSTF also recommends behavioral counseling on healthy diet and activity for adults with cardiovascular risk factors.

Diet (Dietary Guidelines for Americans, 2025–2030)

Released January 7, 2026, the guidelines emphasize whole, minimally processed foods ("eat real food") : vegetables, fruits, whole grains, adequate protein (about 1.2–1.6 g/kg/day), and dairy, while keeping saturated fat below 10% of calories , sodium below 2,300 mg/day , and added sugars to a minimum. They advise drinking less alcohol without setting a numeric limit. Any sustainable calorie deficit (Mediterranean, DASH, lower-carbohydrate) works; adherence matters more than the specific pattern.

Physical Activity (Physical Activity Guidelines, 2nd Edition)

150–300 minutes per week of moderate aerobic activity (or 75–150 minutes vigorous), plus muscle strengthening on 2 or more days .

Older adults add balance training to prevent falls.

Pregnancy and postpartum: at least 150 minutes of moderate activity weekly unless contraindicated.

Weight maintenance after loss often needs more activity, about 200–300 minutes weekly.

Stress, Sleep, and Healthy Habits

Chronic stress and short sleep (under 7 hours) increase appetite hormones and weight gain. Recommend stress-reduction techniques (mindfulness, CBT, social support), consistent sleep, tobacco cessation, and moderation or avoidance of alcohol.

Anti-Obesity Medications

Indicated for a BMI of 30 or higher, or 27 or higher with a weight-related condition , together with lifestyle change.

Drug Typical Weight Loss Key Safety Points

Semaglutide 2.4 mg weekly (GLP-1 receptor agonist) About 15% GI effects, gallbladder disease, pancreatitis; boxed warning for thyroid C-cell tumors (avoid with personal or family history of medullary thyroid cancer or MEN2); stop at least 2 months before planned conception

Tirzepatide (GIP/GLP-1 agonist) About 20% Same class warnings; reduces oral contraceptive absorption : use a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase

Liraglutide 3 mg daily About 5%–8% Daily injection

Phentermine-topiramate ER About 8%–10% REMS : topiramate causes oral clefts , so a negative pregnancy test before starting and reliable contraception are required; avoid with glaucoma or hyperthyroidism

Naltrexone-bupropion About 5% Boxed warning for suicidal thoughts; lowers seizure threshold; avoid with uncontrolled hypertension or opioid use

Orlistat About 3%–5% Oily stools; take a fat-soluble vitamin supplement

GLP-1 drugs slow gastric emptying, which can affect oral drug absorption, and rapid weight loss can restore ovulation in women with PCOS or obesity, producing unplanned pregnancies. Every anti-obesity medication is contraindicated in pregnancy , so contraception counseling is part of prescribing.

Bariatric (Metabolic) Surgery

Indications (ASMBS/IFSO 2022): BMI of 35 or higher regardless of comorbidity, or 30–34.9 with metabolic disease ; lower thresholds apply to Asian patients. Sleeve gastrectomy is the most common procedure, followed by Roux-en-Y gastric bypass.

Reproductive counseling:

Fertility often improves quickly, so delay pregnancy 12–18 months after surgery, during rapid weight loss.

After a malabsorptive procedure (Roux-en-Y), oral contraceptives may be absorbed poorly ( US MEC Category 3 for combined and progestin-only pills), so prefer LARC, the patch, the ring, or DMPA.

Monitor iron, B12, folate, vitamin D, and calcium, and supplement lifelong.

In pregnancy after gastric bypass, avoid the glucose-load screening test (dumping syndrome) and evaluate abdominal pain promptly for internal hernia.

Counseling Approach: The 5 As

Ask permission to discuss weight, and avoid stigmatizing language.

Assess BMI, waist circumference, related conditions, readiness to change, and root causes (sleep, mood, medications, stress, food insecurity).

Advise on health benefits of modest weight loss and treatment options, including behavioral programs, medications, and surgery.

Agree on realistic, specific goals (for example, a 5% loss in 6 months or 150 minutes of walking weekly) using motivational interviewing.

Assist and arrange referrals (dietitian, behavioral program, obesity medicine, bariatric surgery) and follow-up.

Weight bias in health care leads patients to delay care and avoid screening, so a respectful, chronic-disease approach improves outcomes.